The HLA-DQA1*05 genotype does not influence the clinical response to ustekinumab and vedolizumab

Navajas Hernández, Pilar; Pino Bellido, Pilar del; Lorenzo González, Laura; González Rodríguez, Concepción; Pérez Pérez, Antonio; Argüelles Arias, Federico.
Rev. esp. enferm. dig ; 115(11): 608-614, 2023. ilus, tab, graf
Artículo en Inglés | IBECS (España) | ID: ibc-227504

Documentos relacionados

  1. The HLA-DQA1*05 genotype does not influence the clinical response to ustekinumab and vedolizumab.
  2. Characteristics of Facilities With Early and Rapid Ustekinumab Adoption for Patients With Inflammatory Bowel Disease.
  3. Treatment persistence of ustekinumab and vedolizumab in IBD patients is independent of prior immunogenicity to anti-TNFs: a retrospective study.
  4. An update on the role of anti-IL-12/IL23 agents in the management of inflammatory bowel disease.
  5. Validation of a rapid HLA-DQA1*05 pharmacogenomics assay to identify at-risk resistance to anti-tumor necrosis factor therapy among patients with inflammatory bowel disease.
  6. [Advances in the management of inflammatory bowel diseases].
  7. Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease.
  8. Comorbidity Influences the Comparative Safety of Biologic Therapy in Older Adults With Inflammatory Bowel Diseases.
  9. Prospective observational study on Stelara (ustekinumab) assessing effectiveness in Crohn's disease (PROSE): a 16-week follow-up.
  10. Combination therapy of ustekinumab and immunomodulator for inflammatory bowel disease: concerns about the different results observed between two meta-analyses.